FTRE vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
FTRE exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 2/9, indicating poor financial health and operational deterioration. While valuation metrics like Price/Sales (0.32) and PEG (0.34) suggest the stock is deeply undervalued, this is offset by negative revenue growth (-5.20%), a negative ROE of -102.41%, and a current ratio below 1.0 (0.98), signaling liquidity risks. Despite a 'Buy' consensus from analysts with a target of $13.21, the combination of C-suite insider selling and a consistent failure to meet earnings estimates suggests a high-risk profile.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
FTRE vs JNJ: Head-to-Head Comparison
This page compares Fortrea Holdings Inc. (FTRE) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.